Effect of CYP3A51/3 polymorphism on blood pressure in renal transplant recipients.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Transplantation Proceedings

• Publication date

  2012-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.transproceed.2012.09.047PMID 23146466
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Association of the CYP3A5 polymorphism (6986G>A) with blood pressure and hypertension

  2011cited by this paper
• Association Between CYP3A5 Polymorphisms and Blood Pressure in Kidney Transplant Recipients Receiving Calcineurin Inhibitors

  2011cited by this paper
• Functional polymorphisms in the CYP3A4, CYP3A5, and CYP21A2 genes in the risk for hypertension in pregnancy.

  2010cited by this paper
• Effect of CYP3A5 genotype on renal allograft recipients treated with tacrolimus.

  2009cited by this paper
• CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients

  2008cited by this paper
• CYP3A5 GENETIC POLYMORPHISMS IN DIFFERENT ETHNIC POPULATIONS

  2005cited by this paper
• The effect of variable CYP3A5 expression on cyclosporine dosing, blood pressure and long-term graft survival in renal transplant patients.

  2004cited by this paper
• Influence of CYP3A5 and MDR1 (ABCB1) Polymorphisms on the Pharmacokinetics of Tacrolimus in Renal Transplant Recipients

  2004cited by this paper
• Antihypertensive Treatments Obscure Familial Contributions to Blood Pressure Variation

  2003cited by this paper
• Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

  2003cited by this paper
• The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.

  2003cited by this paper
• Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression

  2001cited by this paper

• Model based dosing of tacrolimus after renal transplantation

  2019cites this paper
• Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of Tacrolimus in Kidney Transplantation

  2018cites this paper
• CYP3A5 polymorphisms in renal transplant recipients: influence on tacrolimus treatment

  2018cites this paper
• Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: recent developments and ethnic considerations

  2016cites this paper
• A low-cost, high-quality new drug discovery process using patient-derived induced pluripotent stem cells.

  2015cites this paper
• Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing

  2015cites this paper
• The Role of Pharmacogenetics in the Disposition of and Response to Tacrolimus in Solid Organ Transplantation

  2014cites this paper
• Calcineurin inhibitors and hypertension: a role for pharmacogenetics?

  2014cites this paper